For patients with Upper Tract Urothelial Carcinoma (UTUC), treatment options are extremely limited—so much so that over 80% must undergo kidney removal due to a lack of effective therapies.

TU-1001 has the potential to change that. As the first non-invasive, non-surgical therapy for UTUC, it could offer a groundbreaking alternative to current treatments, which rely on repeated surgeries and invasive procedures. Without TU-1001, patients will continue to face high healthcare costs, increased risks, and a significant impact on their quality of life. Our goal is to provide a safer, more effective solution that preserves kidney function and improves patient outcomes.